Drug news
GSK recalls FluLaval Quadrivalent Influenza vaccine in the US
Glaxo Smith Kline has recalled doses of its FluLaval Quadrivalent flu vaccine due to effectiveness problems. GSK has announced that its vaccine can lose potency with time, so failing to protect against some strains of influenza. The Flulaval Quadrivalent Thimerosal-free vaccine in prefilled syringes is designed to protect against four strains of influenza virus. This recall affects about 1.7 million doses - about 7% of the 24 million doses GSK distributed in the US.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins